Silexion Therapeutics Corp received an updated ownership report from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of the close of business on June 30, 2026, the reporting persons state they may be deemed to have beneficial ownership of no Ordinary Shares, representing 0.0% of the outstanding class. They hold two warrants for 32,500 and 38,920 Ordinary Shares, respectively, but these are not exercisable until stockholder approval of the underlying share issuances and each is subject to a 9.99% beneficial ownership blocker. Without these blocker provisions and assuming exercisability, they indicate potential beneficial ownership of 71,420 Ordinary Shares, yet currently report no voting or dispositive power over any shares.
Positive
None.
Negative
None.
Key Figures
Beneficially owned shares:0 Ordinary SharesPercent of class:0.0%Intracoastal Warrant 1:32,500 Ordinary Shares+3 more
6 metrics
Beneficially owned shares0 Ordinary SharesAs of close of business on June 30, 2026
Percent of class0.0%Reported beneficial ownership of Silexion Ordinary Shares
Intracoastal Warrant 132,500 Ordinary SharesOrdinary Shares issuable upon exercise, subject to stockholder approval and blocker
Intracoastal Warrant 238,920 Ordinary SharesOrdinary Shares issuable upon exercise, subject to stockholder approval and blocker
Potential warrant coverage71,420 Ordinary SharesTotal shares underlying both warrants absent blocker and exercisability limits
Beneficial ownership blocker9.99%Maximum beneficial ownership allowed upon warrant exercise
Key Terms
beneficial ownership, blocker provision, beneficial ownership of more than 9.99%, warrant, +1 more
5 terms
beneficial ownershipfinancial
"each of the Reporting Persons may have been deemed to have beneficial ownership of no Ordinary Shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
blocker provisionfinancial
"Intracoastal Warrant 1 also contains a blocker provision under which the holder thereof does not have the right to exercise"
beneficial ownership of more than 9.99%financial
"any of the holder's affiliates, of more than 9.99% of the Ordinary Shares"
warrantfinancial
"32,500 Ordinary Shares issuable upon exercise of a warrant held by Intracoastal"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
Ordinary Sharesfinancial
"Ordinary shares, par value $0.135 per share"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
What ownership in Silexion Therapeutics Corp (SLXN) do the reporting persons disclose?
They report beneficial ownership of no Ordinary Shares of Silexion Therapeutics Corp, representing 0.0% of the class as of June 30, 2026, with no sole or shared voting or dispositive power reported.
What warrants related to SLXN does Intracoastal Capital LLC hold?
Intracoastal holds two warrants for Silexion: one for 32,500 Ordinary Shares (Intracoastal Warrant 1) and another for 38,920 Ordinary Shares (Intracoastal Warrant 2), both contingent on stockholder approval and subject to a 9.99% blocker.
Why are the SLXN warrants excluded from current beneficial ownership?
They are excluded because each warrant is not exercisable until the effective date of stockholder approval for the underlying share issuances and includes a 9.99% beneficial ownership blocker, limiting exercisability above that threshold.
What potential SLXN ownership is referenced if blockers and conditions did not apply?
Without the blocker provisions and assuming both warrants were exercisable, the reporting persons state they may have been deemed to beneficially own 71,420 Ordinary Shares, though they currently report 0.0% of the class.
What is the reported percentage of class owned in Silexion Therapeutics (SLXN)?
The filing states the reporting persons’ beneficial ownership is 0.0% of Silexion’s Ordinary Shares, and confirms they have 0 sole or shared power to vote or dispose of any shares as of June 30, 2026.
What is the beneficial ownership limitation applied to the SLXN warrants?
Each Intracoastal warrant includes a 9.99% beneficial ownership blocker, preventing exercise to the extent it would cause the holder and certain related parties to own more than 9.99% of Silexion’s Ordinary Shares.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Silexion Therapeutics Corp
(Name of Issuer)
Ordinary shares, par value $0.135 per share
(Title of Class of Securities)
G1281K114
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
G1281K114
1
Names of Reporting Persons
Mitchell P. Kopin
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
G1281K114
1
Names of Reporting Persons
Daniel B. Asher
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP Number(s):
G1281K114
1
Names of Reporting Persons
Intracoastal Capital LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
0.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Silexion Therapeutics Corp
(b)
Address of issuer's principal executive offices:
12 Abba Hillel Road, Ramat-Gan, Israel 5250606
Item 2.
(a)
Name of person filing:
This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)
Address or principal business office or, if none, residence:
The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)
Citizenship:
Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)
Title of class of securities:
Ordinary shares, par value $0.135 per share
(e)
CUSIP No.:
G1281K114
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
As of the close of business on June 30, 2026, each of the Reporting Persons may have been deemed to have beneficial ownership of no Ordinary Shares. The foregoing excludes (I) 32,500 Ordinary Shares issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1") because Intracoastal Warrant 1 is not exercisable until the effective date of stockholder approval of the issuance of the Ordinary Shares issuable upon exercise of Intracoastal Warrant 1 (and Intracoastal Warrant 1 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares) and (II) 38,920 Ordinary Shares issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 2") because Intracoastal Warrant 2 is not exercisable until the effective date of stockholder approval of the issuance of the Ordinary Shares issuable upon exercise of Intracoastal Warrant 2 (and Intracoastal Warrant 2 also contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Ordinary Shares). Without such blocker provision (and assuming each of Intracoastal Warrant 1 and Intracoastal Warrant 2 was currently exercisable), each of the Reporting Persons may have been deemed to have beneficial ownership of 71,420 Ordinary Shares.
(b)
Percent of class:
0.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.